drugset / Trial / NCT04627025

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025

Phase 3 Completed 164 enrolled VectivBio AG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.

Timeline

Start
2021-01-26
Primary completion
2024-01-02
Completion
2024-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Apraglutide Peptide Subcutaneous

Indications